Sequence 5 from Patent US 20200079827

General Information


DRACP ID  DRACP01501

Peptide Name   Sequence 5 from Patent US 20200079827

Sequence  ILKKWWKTSKGLLGGLLGKVTSVIKGLNNI

Sequence Length  30

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic construct

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antimicrobial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01501

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C154H262N40O37

Absent amino acids  ACDEFHMPQRY

Common amino acids  KL

Mass  378349

Pl  11.5

Basic residues  6

Acidic residues  0

Hydrophobic residues  13

Net charge  6

Boman Index  320

Hydrophobicity  25

Aliphatic Index  136.33

Half Life 
  Mammalian: 20 hour
  Yeast: 30 min
  E.coli: >10 hour

Extinction Coefficient cystines  11000

Absorbance 280nm  379.31

Polar residues  11

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2020/0079827 A1

Patent Title  Novel Antimicrobial And Anti-cancer Therapy

Other Iinformation  Granted Patent Family: 6s / 6ex; Family Jurisdictions: EP, IL, AU, US, AT, DEUS, EP, CN, WO; Legal Status: Active; Application No: 201716462586; Filed:Nov 21, 2017; Published: Mar 12, 2020; Earliest Priority: Nov 21, 2016; Granted: Mar 29, 2022

Other Published ID  WO2018094403A1  CN109996554A  EP3541405A1  EP3541405A4 




DRACP is developed by Dr.Zheng's team.